Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 3/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.32 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 7/20 | 0.32 |
| ▸ | CNR1 | P21554 | 5/20 | 0.32 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19251153 | 0.94 | MAPT (0.30) | — | |
| SCHEMBL22752366 | 0.94 | CNR2 (0.33) | CNR2CNR1NR5A1 | |
| SCHEMBL22778499 | 0.94 | CNR2 (0.33) | CNR2CNR1NR5A1 | |
| SCHEMBL19251374 | 0.94 | CNR2 (0.33) | CNR2CNR1NR5A1 | |
| SCHEMBL19251172 | 0.92 | CNR2 (0.32) | CNR2CNR1NR5A1 | |
| SCHEMBL19251313 | 0.92 | CNR2 (0.31) | CNR2CNR1 | |
| SCHEMBL22752329 | 0.91 | CNR2 (0.32) | CNR2CNR1NR5A1 | |
| SCHEMBL19252846 | 0.90 | CNR1 (0.30) | CNR2CNR1 | |
| SCHEMBL19251222 | 0.87 | — | — | |
| SCHEMBL22752671 | 0.84 | MAPT (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-08 | — | — | US | disclosed |
| US-9732083-B2 | Tricyclic gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10858360-B2 | Tricyclic gyrase inhibitors | TOP1, TOP2A, TOP2B | S1PR4 4593/4885S1PR1 4205/4885S1PR3 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.